Tazemetostat
- Generic Name
- Tazemetostat
- Brand Names
- Tazverik
- Drug Type
- Small Molecule
- Chemical Formula
- C34H44N4O4
- CAS Number
- 1403254-99-8
- Unique Ingredient Identifier
- Q40W93WPE1
- Background
Tazemetostat is a methyltransferase inhibitor used to treat metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. Tazemetostat was first named in literature as EPZ-6438.
Tazemetaostat was granted FDA approval on 23 January 2020.
- Indication
Tazemetostat is indicated to treat adult and pediatric patients 16 years and older with metastatic or locally advanced epithelioid sarcoma that is not eligible for complete resection. It is also indicated to treat adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an IZH2 mutation and who have received at least 2 pri...
- Associated Conditions
- Locally Advanced Epithelioid Sarcoma, Metastatic Epithelioid Sarcoma, Refractory Follicular Lymphoma, Relapsed Follicular Lymphoma
- Associated Therapies
- -
A Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2017-01-04
- Last Posted Date
- 2022-11-10
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 7
- Registration Number
- NCT03009344
- Locations
- 🇯🇵
Eisai Trial Site, Chuo-ku, Tokyo, Japan
Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell and Follicular Lymphoma Patients Treated by Chemiotherapy
- Conditions
- Interventions
- First Posted Date
- 2016-09-05
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- The Lymphoma Academic Research Organisation
- Target Recruit Count
- 214
- Registration Number
- NCT02889523
- Locations
- 🇫🇷
APHP - Hôpital Saint Louis, Paris Cedex 10, France
🇫🇷Centre Henri Becquerel, Rouen, France
🇫🇷Institut Gustave Roussy, Villejuif, France
A Study to Assess the Long-term Safety of Tazemetostat
- First Posted Date
- 2016-08-23
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Epizyme, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT02875548
- Locations
- 🇺🇸
California Cancer Associates For Research And Excellence, cCARE, Santa Fe, California, United States
🇺🇸Central Care Cancer Center, Bolivar, Missouri, United States
🇺🇸Astera Cancer Center, East Brunswick, New Jersey, United States
Study of the EZH2 Inhibitor Tazemetostat in Malignant Mesothelioma
- First Posted Date
- 2016-08-09
- Last Posted Date
- 2021-04-09
- Lead Sponsor
- Epizyme, Inc.
- Target Recruit Count
- 74
- Registration Number
- NCT02860286
- Locations
- 🇺🇸
University of California, Los Angeles, Los Angeles, California, United States
🇺🇸City of Hope National Medical Center, Los Angeles, California, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma
- Conditions
- Malignant Rhabdoid Tumors (MRT)Rhabdoid Tumors of the Kidney (RTK)Synovial SarcomaINI1-negative TumorsMalignant Rhabdoid Tumor of OvaryRenal Medullary CarcinomaEpithelioid SarcomaAtypical Teratoid Rhabdoid Tumors (ATRT)Poorly Differentiated Chordoma (or Other Chordoma With Sponsor Approval)Any Solid Tumor With an EZH2 GOF Mutation
- Interventions
- First Posted Date
- 2015-11-11
- Last Posted Date
- 2024-07-01
- Lead Sponsor
- Epizyme, Inc.
- Target Recruit Count
- 267
- Registration Number
- NCT02601950
- Locations
- 🇫🇷
Institut Curie, Paris, France
🇧🇪University Hospital Leuven, Leuven, Belgium
🇫🇷Centre Leon Berard, Lyon, France
EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma
- Conditions
- Interventions
- First Posted Date
- 2015-11-11
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- Epizyme, Inc.
- Target Recruit Count
- 109
- Registration Number
- NCT02601937
- Locations
- 🇨🇦
The Hospital for Sick Children, Toronto, Ontario, Canada
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Texas Children's Cancer and Hematology Center, Houston, Texas, United States
A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2014-08-20
- Last Posted Date
- 2020-01-27
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 96
- Registration Number
- NCT02220842
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸Sloan Kettering Cancer Center, New York, New York, United States
🇫🇷Hôpital Saint-Louis, Paris, France
Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL
- First Posted Date
- 2013-07-12
- Last Posted Date
- 2024-03-26
- Lead Sponsor
- Epizyme, Inc.
- Target Recruit Count
- 400
- Registration Number
- NCT01897571
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.